Virtually all cancer treatments are designed to killcancer cells, usually by inducing apoptosis. However, oneparticular cancer—acute promyelocytic leukemia (APL)—has been successfully treated with all-trans-retinoic acid, which causes the promyelocytes to differentiate into neu-trophils. How might a change in the state of differentiation of APL cancer cells help the patient?

Virtually all cancer treatments are designed to killcancer cells, usually by inducing apoptosis. However, oneparticular cancer—acute promyelocytic leukemia (APL)—has been successfully treated with all-trans-retinoic acid, which causes the promyelocytes to differentiate into neu-trophils. How might a change in the state of differentiation of APL cancer cells help the patient?

Biology: The Dynamic Science (MindTap Course List)

4th Edition

ISBN:9781305389892

Author:Peter J. Russell, Paul E. Hertz, Beverly McMillan

Publisher:Peter J. Russell, Paul E. Hertz, Beverly McMillan

Chapter5: Membranes And Transport

Section: Chapter Questions

Problem 1ITD: Some cancer cells are insensitive to typical chemotherapy. Research into the mechanisms underlying...

See similar textbooks

Similar questions

''In the cellular regulatory pathways that controlcell growth and proliferation, the products of oncogenesare stimulatory components and the products of tumorsuppressor genes are inhibitory components.'' 'Is this statement true? Explain why or why not.
Overexpression of the Myc protein is a common feature of many types of cancer cells, contributing to their excessive cell growth and proliferation. By contrast, when Myc is overexpressed in most normal cells, the result is not excessive proliferation, but cell-cycle arrest or apoptosis.Which one of the following statements provides the most likely explanation for why overexpression of Myc can have such different outcomes in normal cells and in cancer cells? A. Normal cells contain checks and balances that prevent Myc-induced proliferation. B. In normal cells, Myc protein acts as a mediator in cell-cycle arrest and apoptosis. C. The target protein for Myc-induced proliferation is missing from most normal cells. D. In normal cells, when Myc is overexpressed, the excess Myc protein precipitates.
(a) the cell cycle is divided into different phases (referred to as M, G0, G1, S and G2); Can you account for what happens during the different parts of the cycle and out of it is checked? ( b) What is the difference between apoptosis and necrosis? ( c) What are caspases and what is their function in the cell?
The myc oncogene increases expression of the glutamine transporter and glutaminase that converts glutamine to glutamate. How does this contribute to increased proliferation of those cancer cells? What are the reactions and enzymes that are a part of this?
Which component of cell division machinery is frequently targeted by anti-cancer drugs? Can you explain the common side-effects of chemotherapy (e.g. hair loss, mucositis) based on this information?
The expression patterns as well as activation of different types of CDKs happen at different stages of the cell cycle. Explain why.
Paclitaxel stabilizes microtubules by inhibiting the disassembly of the tubulin subunits. What phase of (mitosis) should the cell cycle be arrested in by addition of paclitaxel to dividing cells? Explain
The “Hayflick limit” is the number of times cells growing in tissue culture will divide before cell proliferation ceases. What experimental procedure can be employed to remove this limit?
In cell growth, how does the normal allele of BRCA1 work? Is it an oncogene or a tumor suppressor gene?
Cancer-promoting mutations are likely to have different effects on the activity of proteins encoded byproto-oncogenes than they do on proteins encodedby tumor-suppressor genes. Explain.
p53 can trigger apoptosis if certain cell-cycle events fail. How does this regulatory outcome benefit a multicellular organism?
The tumor suppressor pRB also binds to and suppresses theactivity of retinoblastoma binding protein 2 (RBP2), ahistone demethylase that removes methyl groups from diand trimethylated lysines in histone 3. What is the possibleconsequence of an inactivating mutation in RB1 that causesan inability of pRB to bind RBP2?